Community-wide HIV testing, linkage case management, and defaulter tracing in Bukoba, Tanzania: pre-intervention and post-intervention, population-based survey evaluation.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
21
11
2019
revised:
03
05
2020
accepted:
13
05
2020
pubmed:
6
9
2020
medline:
21
10
2020
entrez:
5
9
2020
Statut:
ppublish
Résumé
Community randomised trials have had mixed success in implementing combination prevention strategies that diagnose 90% of people living with HIV, initiate and retain on antiretroviral therapy (ART) 90% of those diagnosed, and achieve viral load suppression in 90% of those on ART (90-90-90). The Bukoba Combination Prevention Evaluation (BCPE) aimed to achieve 90-90-90 in Bukoba Municipal Council, Tanzania, by scaling up new HIV testing, linkage, and retention interventions. We did population-based, cross-sectional surveys before and after our community-wide intervention in Bukoba-a mixed urban and rural council of approximately 150 000 residents located on the western shore of Lake Victoria in Tanzania. BCPE interventions were implemented in 11 government-supported health-care facilities throughout Bukoba from Oct 1, 2014, to March 31, 2017, when national ART-eligibility guidelines expanded from CD4 counts of less than 350 cells per μL (Oct 1, 2014-Dec 31, 2015) and 500 or less cells per μL (Jan 1, 2016-Sept 30, 2016) to any CD4 cell count (test and treat, Oct 1, 2016-March 31, 2017). We used pre-intervention (Nov 4, 2013-Jan 25, 2014) and post-intervention (June 21, 2017-Sept 20, 2017) population-based household surveys to assess population prevalence of undiagnosed HIV infection and ART coverage, and progress towards 90-90-90, among residents aged 18-49 years. During the 2·5-year intervention, BCPE did 133 695 HIV tests, diagnosed and linked 3918 people living with HIV to HIV care at 11 Bukoba facilities, and returned to HIV care 604 patients who had stopped care. 4795 and 5067 residents aged 18-49 years participated in pre-intervention and post-intervention surveys. HIV prevalence before and after the intervention was similar: pre-intervention 8·9% (95% CI 7·5-10·4); post-intervention 8·4% (6·9-9·9). Prevalence of undiagnosed HIV infection decreased from 4·7% to 2·0% (prevalence ratio 0·42, 95% CI 0·31-0·57), and current ART use among all people living with HIV increased from 32·2% to 70·9% (2·20, 1·82-2·66) overall, 23·0% to 62·1% among men (2·70, 1·84-3·96), and 16·7% to 64·4% among people aged 18-29 years (3·87, 2·54-5·89). Of 436 and 435 people living with HIV aged 18-49 years who participated in pre-intervention and post-intervention surveys, previous HIV diagnosis increased from 47·4% (41·3-53·4) to 76·2% (71·8-80·6), ART use among diagnosed people living with HIV increased from 68·0% (60·9-75·2) to 93·1% (90·2-96·0), and viral load suppression of those on ART increased from 88·7% (83·6-93·8) to 91·3% (88·6-94·1). BCPE findings suggest scaling up recommended HIV testing, linkage, and retention interventions can help reduce prevalence of undiagnosed HIV infection, increase ART use among all people living with HIV, and make substantial progress towards achieving 90-90-90 in a relatively short period. BCPE facility-based testing and linkage interventions are undergoing national scale up to help achieve 90-90-90 in Tanzania. US Presidents' Emergency Plan for AIDS Relief.
Sections du résumé
BACKGROUND
Community randomised trials have had mixed success in implementing combination prevention strategies that diagnose 90% of people living with HIV, initiate and retain on antiretroviral therapy (ART) 90% of those diagnosed, and achieve viral load suppression in 90% of those on ART (90-90-90). The Bukoba Combination Prevention Evaluation (BCPE) aimed to achieve 90-90-90 in Bukoba Municipal Council, Tanzania, by scaling up new HIV testing, linkage, and retention interventions.
METHOD
We did population-based, cross-sectional surveys before and after our community-wide intervention in Bukoba-a mixed urban and rural council of approximately 150 000 residents located on the western shore of Lake Victoria in Tanzania. BCPE interventions were implemented in 11 government-supported health-care facilities throughout Bukoba from Oct 1, 2014, to March 31, 2017, when national ART-eligibility guidelines expanded from CD4 counts of less than 350 cells per μL (Oct 1, 2014-Dec 31, 2015) and 500 or less cells per μL (Jan 1, 2016-Sept 30, 2016) to any CD4 cell count (test and treat, Oct 1, 2016-March 31, 2017). We used pre-intervention (Nov 4, 2013-Jan 25, 2014) and post-intervention (June 21, 2017-Sept 20, 2017) population-based household surveys to assess population prevalence of undiagnosed HIV infection and ART coverage, and progress towards 90-90-90, among residents aged 18-49 years.
FINDINGS
During the 2·5-year intervention, BCPE did 133 695 HIV tests, diagnosed and linked 3918 people living with HIV to HIV care at 11 Bukoba facilities, and returned to HIV care 604 patients who had stopped care. 4795 and 5067 residents aged 18-49 years participated in pre-intervention and post-intervention surveys. HIV prevalence before and after the intervention was similar: pre-intervention 8·9% (95% CI 7·5-10·4); post-intervention 8·4% (6·9-9·9). Prevalence of undiagnosed HIV infection decreased from 4·7% to 2·0% (prevalence ratio 0·42, 95% CI 0·31-0·57), and current ART use among all people living with HIV increased from 32·2% to 70·9% (2·20, 1·82-2·66) overall, 23·0% to 62·1% among men (2·70, 1·84-3·96), and 16·7% to 64·4% among people aged 18-29 years (3·87, 2·54-5·89). Of 436 and 435 people living with HIV aged 18-49 years who participated in pre-intervention and post-intervention surveys, previous HIV diagnosis increased from 47·4% (41·3-53·4) to 76·2% (71·8-80·6), ART use among diagnosed people living with HIV increased from 68·0% (60·9-75·2) to 93·1% (90·2-96·0), and viral load suppression of those on ART increased from 88·7% (83·6-93·8) to 91·3% (88·6-94·1).
INTERPRETATION
BCPE findings suggest scaling up recommended HIV testing, linkage, and retention interventions can help reduce prevalence of undiagnosed HIV infection, increase ART use among all people living with HIV, and make substantial progress towards achieving 90-90-90 in a relatively short period. BCPE facility-based testing and linkage interventions are undergoing national scale up to help achieve 90-90-90 in Tanzania.
FUNDING
US Presidents' Emergency Plan for AIDS Relief.
Identifiants
pubmed: 32888413
pii: S2352-3018(20)30199-5
doi: 10.1016/S2352-3018(20)30199-5
pmc: PMC7748378
mid: NIHMS1651582
pii:
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e699-e710Subventions
Organisme : NCHHSTP CDC HHS
ID : U2G PS001998
Pays : United States
Organisme : CDC HHS
ID : 5UGPS001998-05
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
MMWR Morb Mortal Wkly Rep. 2018 Jun 15;67(23):663-667
pubmed: 29902168
AIDS Behav. 2017 Aug;21(8):2551-2560
pubmed: 28299518
AIDS. 2018 Jan 28;32(3):363-369
pubmed: 29194115
JAMA. 2017 Jun 6;317(21):2196-2206
pubmed: 28586888
PLoS One. 2018 Aug 10;13(8):e0197904
pubmed: 30096139
PLoS One. 2018 Dec 13;13(12):e0208919
pubmed: 30543693
PLoS One. 2019 May 2;14(5):e0215654
pubmed: 31048912
Sex Transm Dis. 2013 Dec;40(12):909-14
pubmed: 24220349
Lancet HIV. 2017 Feb;4(2):e74-e82
pubmed: 27913227
PLoS Med. 2017 May 2;14(5):e1002292
pubmed: 28464041
PLoS One. 2014 Jan 28;9(1):e86719
pubmed: 24489776
AIDS Care. 2017 Oct;29(10):1198-1204
pubmed: 28325077
MMWR Morb Mortal Wkly Rep. 2019 Aug 02;68(30):658-663
pubmed: 31369522
PLoS One. 2016 Feb 24;11(2):e0150086
pubmed: 26910847
BMJ Open. 2015 Jun 24;5(6):e006927
pubmed: 26109110
BMC Infect Dis. 2016 Sep 20;16:497
pubmed: 27646635
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
AIDS. 2017 Apr 24;31(7):1017-1024
pubmed: 28252526
MMWR Morb Mortal Wkly Rep. 2017 Jun 02;66(21):558-563
pubmed: 28570507
AIDS Behav. 2017 Jun;21(6):1745-1754
pubmed: 27578001